Opposition Filed
Opposition filed by Teva Pharmaceutical Industries Ltd
EP Register Verified
SPARSENTAN FOR USE IN THE TREATMENT OF ALPORT SYNDROME
Publication No.
EP3525784
•
App No.
EP17791821
•
Filed by
Travere Therapeutics, Inc.
•
Filed on
2017-10-13
•
Issued/Published on
2026-01-28
Publication No.
EP3525784
A1
Application No.
EP17791821
Filed: 2017-10-13
Grant Date
2026-01-28
Mention of grant
Active Oppositions
1 Active
EPO Oppositions
Patent Abstract / Summary
Patent abstract is being processed or was not provided in English by the publishing office.
IPC Classifications
A61K31/422, A61P13/12, A61P43/00
A61K31/422, A61P13/12
Priority Claims
US 201662407860P
Date: 2016-10-13
US 201662423079P
Date: 2016-11-16
Designated Contracting States (38 EPC States)
Albania
(AL)
Austria
(AT)
Belgium
(BE)
Bulgaria
(BG)
Switzerland
(CH)
Cyprus
(CY)
Czech Republic
(CZ)
Germany
(DE)
Denmark
(DK)
Estonia
(EE)
Spain
(ES)
Finland
(FI)
France
(FR)
United Kingdom
(GB)
Greece
(GR)
Croatia
(HR)
Hungary
(HU)
Ireland
(IE)
Iceland
(IS)
Italy
(IT)
Liechtenstein
(LI)
Lithuania
(LT)
Luxembourg
(LU)
Latvia
(LV)
Monaco
(MC)
North Macedonia
(MK)
Malta
(MT)
Netherlands
(NL)
Norway
(NO)
Poland
(PL)
Portugal
(PT)
Romania
(RO)
Serbia
(RS)
Sweden
(SE)
Slovenia
(SI)
Slovakia
(SK)
San Marino
(SM)
Turkey
(TR)
Parties & Representation
Applicants
Travere Therapeutics, Inc.
3611 Valley Centre Drive Suite 300, San Diego CA 92130
USRetrophin, Inc.
3721 Valley Center Drive, Suite 200
USInventors (2)
KOMERS, Radko
01205 SW Mary Failing Drive, Portland, Oregon 97219
USSHIH, Alvin
1538 Beacon Street, Newton, Massachusetts 02468
USRepresentatives / Agents
Potter Clarkson
Chapel Quarter, Mount Street
GBElkington and Fife LLP
Prospect House, 8 Pembroke Road
GBKey Procedural Dates
Request-For-Examination
2019-04-26
Mention Of Grant Published
2026-01-28
First-Examination-Report-Despatched
2020-06-09
Patent Oppositions
Official opposition proceedings filed against European Patent EP3525784 under EPC Article 99.
#1
Opponent
Company
Teva Pharmaceutical Industries Ltd
124 Dvora HaNevi'a St., IL
Representative
Elkington and Fife LLP
Filing
Date
Opposition in Progress
2026-10-16
Legal Status & Event History
Official European Patent Office legal and procedural status changes recorded for this file.
| Date | Code | Event Description | Auth |
|---|---|---|---|
| 2019-08-21 | AX | REQUEST FOR EXTENSION OF THE EUROPEAN PATENT | EP |
| 2019-08-21 | AK | DESIGNATED CONTRACTING STATES | EP |
| 2019-08-21 | 17P | REQUEST FOR EXAMINATION FILED | EP |
| 2020-07-08 | 17Q | FIRST EXAMINATION REPORT DESPATCHED | EP |
| 2020-07-31 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2019-07-19 | PUAI | PUBLIC REFERENCE MADE UNDER ARTICLE 153(3) EPC TO A PUBLISHED INTERNATIONAL APPLICATION THAT HAS ENTERED THE EUROPEAN PHASE | EP |
| 2020-06-05 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2019-07-19 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2018-04-20 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2017-11-10 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2021-06-09 | RAP3 | PARTY DATA CHANGED (APPLICANT DATA CHANGED OR RIGHTS OF AN APPLICATION TRANSFERRED) | EP |
| 2023-08-02 | P01 | OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) REGISTERED | EP |
| 2024-02-28 | TPAC | OBSERVATIONS FILED BY THIRD PARTIES | EP |
| 2025-04-01 | GRAP | DESPATCH OF COMMUNICATION OF INTENTION TO GRANT A PATENT | EP |
| 2025-04-01 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2025-04-30 | RIC1 | INFORMATION PROVIDED ON IPC CODE ASSIGNED BEFORE GRANT | EP |
| 2025-05-07 | INTG | INTENTION TO GRANT ANNOUNCED | EP |
| 2025-07-30 | GRAJ | INFORMATION RELATED TO DISAPPROVAL OF COMMUNICATION OF INTENTION TO GRANT BY THE APPLICANT OR RESUMPTION OF EXAMINATION PROCEEDINGS BY THE EPO DELETED | EP |
| 2025-07-30 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2025-09-03 | INTC | INTENTION TO GRANT ANNOUNCED (DELETED) | EP |
| 2025-08-25 | GRAP | DESPATCH OF COMMUNICATION OF INTENTION TO GRANT A PATENT | EP |
| 2025-08-25 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2025-09-24 | INTG | INTENTION TO GRANT ANNOUNCED | EP |
| 2025-12-26 | GRAA | (EXPECTED) GRANT | EP |
| 2025-12-24 | GRAS | GRANT FEE PAID | EP |
| 2025-12-26 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2026-01-28 | AK | DESIGNATED CONTRACTING STATES | EP |
| 2026-01-28 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-02-12 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-02-25 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-05-26 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-06-10 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-06-15 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-06-15 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-07 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-10 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-07-09 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-11 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-10 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-14 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-15 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-17 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-18 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-24 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-28 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-08-18 | VS25 | LAPSED IN A VALIDATION STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NAT. OFFICE TO EPO] | EP |
| 2026-10-06 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-10-13 | VS25 | LAPSED IN A VALIDATION STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NAT. OFFICE TO EPO] | EP |
| 2026-10-17 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-10-21 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-10-27 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-10-27 | PLBI | OPPOSITION FILED | EP |
| 2026-10-28 | REG | REFERENCE TO A NATIONAL CODE | EP |
Patent & Non-Patent Citations
Cited documents and prior art referenced in search and examination reports.
Cited Patent Documents
US2015164865
2015-06-18
Espacenet
Non-Patent Scientific Literature (NPL)
- RADKO KOMERS; HORACIO PLOTKIN: "Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease", AMERICAN JOURNAL OF PHYSIOLOGY - REGULATORY , INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, vol. 310, no. 10, 15 May 2016 (2016-05-15), US, pages R877 - R884, XP055436443, ISSN: 0363-6119, DOI: 10.1152/ajpregu.00425.2015
- YUICHI IKEDA; HIDETOSHI KUMAGAI; YOSHIHIRO MOTOZAWA; JUN-ICHI SUZUKI; ISSEI KOMURO: "Next Generation ARBs. Going Beyond Modulation of the Renin-Angiotensin System", INTERNATIONAL HEART JOURNAL, JAPAN, 1 January 2015 (2015-01-01), Japan, pages 585, XP055436552, Retrieved from the Internet <URL:https://www.jstage.jst.go.jp/article/ihj/56/6/56_15-295/_pdf/-char/en>
- TOBE SHELDON; KOHAN DONALD E.; SINGARAYER RANJIT: "Endothelin Receptor Antagonists: New Hope for Renal Protection?", CURRENT HYPERTENSION REPORTS, vol. 17, no. 7, 12 June 2015 (2015-06-12), GB, pages 1 - 7, XP035489508, ISSN: 1522-6417, DOI: 10.1007/s11906-015-0568-7
- BARTON; M.: "Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans", BBA - MOLECULAR BASIS OF DISEASE, vol. 1802, no. 12, 1 December 2010 (2010-12-01), NL, pages 1203 - 1213, XP027446157, ISSN: 0925-4439, DOI: 10.1016/j.bbadis.2010.03.012
- RADKO KOMERS; DEBBIE S. GIPSON; PETER NELSON; SHARON ADLER; TARAK SRIVASTAVA; VIMAL K. DEREBAIL; KEVIN E. MEYERS; PABLO PERGOLA; M: "Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)", KIDNEY INTERNATIONAL REPORTS, vol. 2, no. 4, 1 July 2017 (2017-07-01), US, pages 654 - 664, XP055436543, ISSN: 2468-0249, DOI: 10.1016/j.ekir.2017.02.019
- HOWARD TRACHTMAN: "Investigational drugs in development for focal segmental glomerulosclerosis", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 26, no. 8, 3 August 2017 (2017-08-03), UK, pages 945 - 952, XP055436456, ISSN: 1354-3784, DOI: 10.1080/13543784.2017.1351544
- SAVIGE JUDY; GREGORY MARTIN; GROSS OLIVER; KASHTAN CLIFFORD; DING JIE; FLINTER FRANCES: "Expert Guidelines for the Management of Alport Syndrome and Thin Basement Membrane Nephropathy", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 24, no. 3, 1 March 2013 (2013-03-01), pages 364 - 375, XP055801246, ISSN: 1046-6673, DOI: 10.1681/ASN.2012020148
- KASHTAN CLIFFORD E., DING JIE, GAROSI GUIDO, HEIDET LAURENCE, MASSELLA LAURA, NAKANISHI KOICHI, NOZU KANDAI, RENIERI ALESSANDRA, R: "Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group", KIDNEY INTERNATIONAL, vol. 93, no. 5, 1 May 2018 (2018-05-01), pages 1045 - 1051, XP093449230, ISSN: 0085-2538, DOI: 10.1016/j.kint.2017.12.018
- D. COSGROVE ET AL: "PO1897: The Dual Endothelin/Angiotensin II Receptor (ETAR/AT1R) Antagonist Sparsentan Slows Renal Disease, Improves Lifespan, and Attenuates Hearing Loss in Alport Mice: Comparison With Losartan and Atrasentan", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, OVID TECHNOLOGIES (WOLTERS KLUWER HEALTH), vol. 31, no. 10S, 1 October 2020 (2020-10-01) - 2020-10-04, pages 589 - 589, XP009569354, ISSN: 1046-6673, DOI: 10.1681/ASN.20203110S1589a
- RETROPHIN; INC.: "Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis", TRAVERE THERAPEUTICS, 7 September 2016 (2016-09-07), pages 1 - 3, XP093141000
- BRIANNA DUFEK; DANIEL T. MEEHAN; DUANE DELIMONT; LINDA CHEUNG; MICHAEL ANNE GRATTON; GRADY PHILLIPS; WENPING SONG; SHIGUANG LIU; D: "Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease", KIDNEY INTERNATIONAL, vol. 90, no. 2, 1 August 2016 (2016-08-01), pages 300 - 310, XP055722132, ISSN: 0085-2538, DOI: 10.1016/j.kint.2016.02.018
- MEEHAN DANIEL T.; DELIMONT DUANE; DUFEK BRIANNA; ZALLOCCHI MARISA; PHILLIPS GRADY; GRATTON MICHAEL ANNE; COSGROVE DOMINIC: "Endothelin-1 mediated induction of extracellular matrix genes in strial marginal cells underlies strial pathology in Alport mice", HEARING RESEARCH, vol. 341, 21 August 2016 (2016-08-21), NL, pages 100 - 108, XP029785932, ISSN: 0378-5955, DOI: 10.1016/j.heares.2016.08.003
- HOEPER M. M.: "Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?", EUROPEAN RESPIRATORY JOURNAL, vol. 34, no. 3, 1 September 2009 (2009-09-01), pages 529 - 530, XP093261653, ISSN: 0903-1936, DOI: 10.1183/09031936.00094409
- BENSTETTER MONIKA; SABINE HAUBENREISSER: "Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury", PRESS RELEASE, EUROPEAN MEDICINES AGENCY, 10 December 2010 (2010-12-10), pages 1 - 2, XP093412614, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/press-release/thelin-sitaxentan-be-withdrawn-due-cases-unpredictable-serious-liver-injury_en.pdf>
- COSGROVE DOMINIC E., MEEHAN DANIEL T., DUFEK BRIANNA M., DELIMONT DUANE C.: "SA-OR048 Mesangial Filopodial Invasion of Glomerular Capillaries in Alport Syndrome", KIDNEY WEEK 2015 JASN ABSTRACT SUPPLEMENT, vol. 26, 1 November 2015 (2015-11-01) - 8 November 2015 (2015-11-08), pages 74 - 74, XP093449329
- LEACH KEVIN, PAN-ZHOU XIN-RU, DEATS WAYNE, BECONI MARIA: "TH-PO166 Renal Pharmacology and Preclinical Attributes of Sparsentan, a Dually Active Endothelin A and Angiotensin 1 Receptor Antagonist", KIDNEY WEEK 2016 JASN ABSTRACT SUPPLEMENT, vol. 27, 1 November 2016 (2016-11-01) - 20 November 2016 (2016-11-20), pages 133 - 133, XP093449334
- KOMERS RADKO, SHIH ALVIN, BELDER RENE: "SA-PO685 Antihypertensive Effects of Sparsentan, a Dual Angiotensin II and Endothelin Type A Receptor Antagonist", KIDNEY WEEK 2016 JASN ABSTRACT SUPPLEMENT, vol. 27, 1 November 2016 (2016-11-01) - 20 November 2016 (2016-11-20), pages 789 - 789, XP093449336
- TRACHTMAN HOWARD, NELSON PETER J., KOMERS RADKO: "HI-OR06 Efficacy and Safety of Sparsentan, a Dual Angiotensin II (Ang II) and Endothelin (ET) Type A Receptor Antagonist, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Phase 2 Trial (DUET)", KIDNEY WEEK 2016 JASN ABSTRACT SUPPLEMENT, vol. 27, 1 November 2016 (2016-11-01) - 20 November 2016 (2016-11-20), US, pages 1164 - 1164, XP093449339
- MCGOON MICHAEL, FROST ADAANI, OUDIZ RONALD, BADESCH DAVID, GALIE NAZZARENO, OLSCHEWSKI HORST, MCLAUGHLIN VALLERIE, GERBER MICHAEL,: "Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities", CHEST, vol. 135, no. 1, 1 January 2009 (2009-01-01), United States, pages 122 - 129, XP009567719, ISSN: 0012-3692, DOI: 10.1378/chest.08-1028
- ERVE JOHN C.; GAUBY SHAWN; MAYNARD JOHN W.; SVENSSON MATS A.; TONN GEORGE; QUINN KEVIN P.: "Bioactivation of Sitaxentan in Liver Microsomes, Hepatocytes, and Expressed Human P450s with Characterization of the Glutathione Conjugate by Liquid Chromatography Tandem Mass Spectrometry", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 26, no. 6, 17 June 2013 (2013-06-17), US, pages 926 - 936, XP093412656, ISSN: 0893-228X, DOI: 10.1021/tx4001144
- KENNA J. GERRY, STAHL SIMONE H., EAKINS JULIE A., FOSTER ALISON J., ANDERSSON LINDA C., BERGARE JONAS, BILLGER MARTIN, ELEBRING MA: "Multiple Compound-Related Adverse Properties Contribute to Liver Injury Caused by Endothelin Receptor Antagonists", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 352, no. 2, 1 February 2015 (2015-02-01), pages 281 - 290, XP093449343, ISSN: 0022-3565, DOI: 10.1124/jpet.114.220491
- LEPIST EVE-IRENE, HUNTER GILLIES, WILLIAM SMITH, JIA HAO, CASSANDRA HUBERT, ROBERT L. ST. CLAIRE III, KENNETH R. BROUWER, ADRIAN S: "Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes", PLOS ONE, vol. 9, no. 1, 30 January 2014 (2014-01-30), pages e87548 - e87548-10, XP093449349, DOI: 10.1371/journal.pone.0087548.g001
- SAVIGE JUDY ET AL: "Expert Guidelines for the Management of Alport Syndrome and Thin Basement Membrane Nephropathy", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 24, no. 3, 1 March 2013 (2013-03-01), US, pages 364 - 375, XP55801246, ISSN: 1046-6673, Retrieved from the Internet <URL:https://jasn.asnjournals.org/content/jnephrol/24/3/364.full.pdf?with-ds=yes> [retrieved on 20210504], DOI: 10.1681/ASN.2012020148
Worldwide Patent Family
Related applications and patents in the same INPADOC worldwide family.
| Country | Publication Number | Kind | Publication Date | Action |
|---|---|---|---|---|
| EP | EP3525784A1 | A1 | 2019-08-21 | Espacenet |
| EP | EP3525784B1 | B1 | 2026-01-28 | Espacenet |
| AU | AU2017341825A1 | A1 | 2019-04-11 | Espacenet |
| AU | AU2017341825B2 | B2 | 2023-06-01 | Espacenet |
| AU | AU2023219839A1 | A1 | 2023-09-07 | Espacenet |
| AU | AU2023219839B2 | B2 | 2025-08-21 | Espacenet |
| AU | AU2025271121A1 | A1 | 2025-12-18 | Espacenet |
| BR | BR112019007576A2 | A2 | 2019-07-02 | Espacenet |
| CA | CA3039819A1 | A1 | 2018-04-19 | Espacenet |
| CN | CN110049764A | A | 2019-07-23 | Espacenet |
| CN | CN114788823A | A | 2022-07-26 | Espacenet |
| CN | CN116983302A | A | 2023-11-03 | Espacenet |
| CN | CN117017985A | A | 2023-11-10 | Espacenet |
| CN | CN117085013A | A | 2023-11-21 | Espacenet |
| EP | EP4744733A2 | A2 | 2026-05-20 | Espacenet |
| EP | EP4744733A3 | A3 | 2026-07-29 | Espacenet |
| ES | ES3067967T3 | T3 | 2026-05-26 | Espacenet |
| JP | JP2019530713A | A | 2019-10-24 | Espacenet |
| JP | JP2022137245A | A | 2022-09-21 | Espacenet |
| JP | JP2022141802A | A | 2022-09-29 | Espacenet |
| JP | JP2025060754A | A | 2025-04-10 | Espacenet |
| KR | KR20220132030A | A | 2022-09-29 | Espacenet |
| KR | KR102528435B1 | B1 | 2023-05-03 | Espacenet |
| KR | KR20190077348A | A | 2019-07-03 | Espacenet |
| KR | KR20230066644A | A | 2023-05-16 | Espacenet |
| KR | KR20240162167A | A | 2024-11-14 | Espacenet |
| MA | MA46524A | A | 2019-08-21 | Espacenet |
| NZ | NZ752061A | A | 2026-05-29 | Espacenet |
| NZ | NZ792807A | A | 2026-05-29 | Espacenet |
| US | US2020281901A1 | A1 | 2020-09-10 | Espacenet |
| US | US10864197B2 | B2 | 2020-12-15 | Espacenet |
| US | US20250325522A1 | A1 | 2025-10-23 | Espacenet |
| US | US12714697B2 | B2 | 2026-08-25 | Espacenet |
| US | US2019262317A1 | A1 | 2019-08-29 | Espacenet |
| US | US2021196688A1 | A1 | 2021-07-01 | Espacenet |
| US | US20250325523A1 | A1 | 2025-10-23 | Espacenet |
| WO | WO2018071784A1 | A1 | 2018-04-19 | Espacenet |
Official File Inspection
EPC Art. 128 Public Dossier
Complete European Patent Register Dossier (148 Total Documents)
The full inspection file for Application EP17791821 contains 148 total documents, including all notices of opposition, proprietor counter-statements, examination communications, third-party observations, and procedural forms. Below are all major recorded procedural filings and publication specifications.
Recorded Filings & Patent Specifications
Official publication specifications, opposition filings, proprietor replies, and procedural submissions.
European Patent Specification - Granted Patent (B1)
Publication Specification
Date: 2026-01-28
Procedure: Grant
EP3525784B1
Official European Patent Register Full Dossier
Publication Specification
Date: 2026-01-28
Procedure: All Proceedings (Examination & Opposition)
EP17791821
European Patent Application with Search Report (A1)
Publication Specification
Date: 2018-04-19
Procedure: Publication
EP3525784A1
Lapse of the patent in a contracting state
Dossier Filing
Date: 2026-10-30
Procedure: Examination
0009250
Lapse of the patent in a contracting state
Dossier Filing
Date: 2026-10-27
Procedure: Examination
0009250
Opposition filed
Dossier Filing
Date: 2026-10-27
Procedure: Opposition
0009260
Lapse of the patent in a contracting state
Dossier Filing
Date: 2026-10-09
Procedure: Examination
0009250
Lapse of the patent in a contracting state
Dossier Filing
Date: 2026-07-31
Procedure: Examination
0009250
Lapse of the patent in a contracting state
Dossier Filing
Date: 2026-07-24
Procedure: Examination
0009250
Lapse of the patent in a contracting state
Dossier Filing
Date: 2026-07-17
Procedure: Examination
0009250
Lapse of the patent in a contracting state
Dossier Filing
Date: 2026-07-10
Procedure: Examination
0009250
Lapse of the patent in a contracting state
Dossier Filing
Date: 2026-06-19
Procedure: Examination
0009250
Change - divisional application(s)
Dossier Filing
Date: 2026-01-30
Procedure: Examination
0008299DANR
(Expected) grant
Dossier Filing
Date: 2025-12-26
Procedure: Grant
0009210
New entry: Payment of fee for grant
Dossier Filing
Date: 2025-12-24
Procedure: Grant
EPIDOSNIGR3
New entry: Payment of fee for publishing/printing
Dossier Filing
Date: 2025-12-24
Procedure: Examination
EPIDOSNIGR5
New entry: Receipt of the translation of the claim(s)
Dossier Filing
Date: 2025-12-24
Procedure: Examination
EPIDOSNIGR7
New entry: Renewal fee paid
Dossier Filing
Date: 2025-10-28
Procedure: Examination
EPIDOSNRFE2
Renewal fee payment
Procedural Step
Date: 2025-10-27
Procedure: Examination
RFEE
Intention to grant the patent
Procedural Step
Date: 2025-08-26
Procedure: Grant
IGRA
New entry: Communication of intention to grant a patent
Dossier Filing
Date: 2025-08-25
Procedure: Grant
EPIDOSNIGR1
Change - German title
Dossier Filing
Date: 2025-08-08
Procedure: Examination
0008199TIDE
Change - French title
Dossier Filing
Date: 2025-08-08
Procedure: Examination
0008199TIFR
Deletion - Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
Dossier Filing
Date: 2025-07-30
Procedure: Grant
EPIDOSDIGR1
DISSAPPROVAL_OF_COMMUNICATION_OF_INTENTION_TO_GRANT_PATENT
Procedural Step
Date: 2025-07-30
Procedure: Grant
IGRE
Change - German title
Dossier Filing
Date: 2025-04-04
Procedure: Examination
0009199TIDE
Change - French title
Dossier Filing
Date: 2025-04-04
Procedure: Examination
0009199TIFR
Intention to grant the patent
Procedural Step
Date: 2025-04-02
Procedure: Grant
IGRA
New entry: Communication of intention to grant a patent
Dossier Filing
Date: 2025-04-01
Procedure: Grant
EPIDOSNIGR1
Change - classification
Dossier Filing
Date: 2025-03-28
Procedure: Examination
0008199IPCL
Change - German title
Dossier Filing
Date: 2025-03-28
Procedure: Examination
0008199TIDE
Change - English title
Dossier Filing
Date: 2025-03-28
Procedure: Examination
0008199TIEN
Change - French title
Dossier Filing
Date: 2025-03-28
Procedure: Examination
0008199TIFR
New entry: Decision on request for further processing
Dossier Filing
Date: 2025-02-20
Procedure: Examination
EPIDOSNRFP4
New entry: Reply to examination report
Dossier Filing
Date: 2025-02-12
Procedure: Examination
EPIDOSNEXR3
New entry: Fee payment for request for further processing
Dossier Filing
Date: 2025-02-12
Procedure: Examination
EPIDOSNRFP2
New entry: Receipt of request for further processing
Dossier Filing
Date: 2025-02-11
Procedure: Examination
EPIDOSNRFP1
Request for further processing
Procedural Step
Date: 2025-02-11
Procedure: Examination
RFPR
New entry: Application deemed to be withdrawn: despatch of communication + time limit
Dossier Filing
Date: 2024-12-12
Procedure: Examination
EPIDOSNADW2
Application deemed to be withdrawn
Procedural Step
Date: 2024-12-11
Procedure: Examination
ADWI
New entry: Renewal fee paid
Dossier Filing
Date: 2024-10-28
Procedure: Examination
EPIDOSNRFE2
Renewal fee payment
Procedural Step
Date: 2024-10-28
Procedure: Examination
RFEE
Change: Despatch of examination report + time limit
Dossier Filing
Date: 2024-07-22
Procedure: Examination
EPIDOSCEXR2
New entry: Despatch of examination report + time limit
Dossier Filing
Date: 2024-05-25
Procedure: Examination
EPIDOSNEXR2
Communication from the examining division
Procedural Step
Date: 2024-05-24
Procedure: Examination
EXRE
New entry: Observations by third parties
Dossier Filing
Date: 2024-02-28
Procedure: Examination
EPIDOSNTIPA
Observations by a third party
Procedural Step
Date: 2024-02-27
Procedure: Examination
TIPA
New entry: Renewal fee paid
Dossier Filing
Date: 2023-10-28
Procedure: Examination
EPIDOSNRFE2
Renewal fee payment
Procedural Step
Date: 2023-10-27
Procedure: Examination
RFEE
New entry: Reply to examination report
Dossier Filing
Date: 2023-06-19
Procedure: Examination
EPIDOSNEXR3
New entry: Despatch of examination report + time limit
Dossier Filing
Date: 2023-03-21
Procedure: Examination
EPIDOSNEXR2
Communication from the examining division
Procedural Step
Date: 2023-03-20
Procedure: Examination
EXRE
New entry: Renewal fee paid
Dossier Filing
Date: 2022-10-28
Procedure: Examination
EPIDOSNRFE2
Renewal fee payment
Procedural Step
Date: 2022-10-27
Procedure: Examination
RFEE
New entry: Renewal fee paid
Dossier Filing
Date: 2021-10-29
Procedure: Examination
EPIDOSNRFE2
Renewal fee payment
Procedural Step
Date: 2021-10-27
Procedure: Examination
RFEE
New entry: Reply to examination report
Dossier Filing
Date: 2021-09-17
Procedure: Examination
EPIDOSNEXR3
New entry: Despatch of examination report + time limit
Dossier Filing
Date: 2021-05-26
Procedure: Examination
EPIDOSNEXR2
Communication from the examining division
Procedural Step
Date: 2021-05-25
Procedure: Examination
EXRE
Change - applicant
Dossier Filing
Date: 2021-05-07
Procedure: Examination
0009199APPR
New entry: Reply to examination report
Dossier Filing
Date: 2020-12-04
Procedure: Examination
EPIDOSNEXR3
New entry: Renewal fee paid
Dossier Filing
Date: 2020-10-28
Procedure: Examination
EPIDOSNRFE2
Renewal fee payment
Procedural Step
Date: 2020-10-27
Procedure: Examination
RFEE
Change: Despatch of examination report + time limit
Dossier Filing
Date: 2020-09-16
Procedure: Examination
EPIDOSCEXR2
Communication from the examining division
Procedural Step
Date: 2020-06-09
Procedure: Examination
EXRE
New entry: Despatch of examination report + time limit
Dossier Filing
Date: 2020-06-05
Procedure: Examination
EPIDOSNEXR2
First examination report
Dossier Filing
Date: 2020-06-05
Procedure: Examination
0009185
Amendment by applicant
Dossier Filing
Date: 2019-11-30
Procedure: Examination
EPIDOS ABEX
Amendments
Procedural Step
Date: 2019-11-27
Procedure: Examination
ABEX
New entry: Renewal fee paid
Dossier Filing
Date: 2019-10-29
Procedure: Examination
EPIDOSNRFE2
Renewal fee payment
Procedural Step
Date: 2019-10-28
Procedure: Examination
RFEE
Publication in section I.1 EP Bulletin
Dossier Filing
Date: 2019-07-19
Procedure: Examination
0009012
The date on which the examining division becomes responsible, has been established
Dossier Filing
Date: 2019-07-19
Procedure: Examination
EPIDOSNEXAM52
Request for examination filed
Dossier Filing
Date: 2019-07-19
Procedure: Examination
0009171
PCT data prior to European publication
Dossier Filing
Date: 2019-06-12
Procedure: Examination
EPIDOS PCT
New entry: Fee payment for extension state
Dossier Filing
Date: 2019-05-11
Procedure: Examination
EPIDOSNEXP2
PCT data prior to European publication
Dossier Filing
Date: 2019-05-11
Procedure: Examination
EPIDOS PCT
New entry: Fee payment for validation state
Dossier Filing
Date: 2019-05-11
Procedure: Examination
EPIDOSNVAP2
Change - representative
Dossier Filing
Date: 2019-04-26
Procedure: Examination
EPIDOS FREP
PCT data prior to European publication
Dossier Filing
Date: 2019-04-26
Procedure: Examination
EPIDOS PCT
Payment of national basic fee
Procedural Step
Date: 2019-04-26
Procedure: Examination
FFEE
Payment of the first designation fee
Procedural Step
Date: 2019-04-26
Procedure: Examination
DEST
Payment of the fee for examination
Procedural Step
Date: 2019-04-26
Procedure: Examination
EXAM_PCT
Validation of the patent
Procedural Step
Date: 2019-04-26
Procedure: Examination
VAPT
Date on which the examining division has become responsible
Procedural Step
Date: 2019-04-26
Procedure: Examination
EXAM52
Extension of the patent
Procedural Step
Date: 2019-04-26
Procedure: Examination
EXPT
PCT data prior to European publication
Dossier Filing
Date: 2018-05-05
Procedure: Examination
EPIDOS PCT
PCT data prior to European publication
Dossier Filing
Date: 2018-04-20
Procedure: Examination
EPIDOS PCT
PCT data prior to European publication
Dossier Filing
Date: 2017-11-10
Procedure: Examination
EPIDOS PCT
Language of the procedure
Procedural Step
Procedure: Examination
PROL
International searching authority
Procedural Step
Procedure: Examination
ISAT